Q-omics provides the consensus-scored NLRP14 profile across patient tissues and cancer cell-line models. NLRP14 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NLRP14 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, NLRP14 RNA expression shows 17,819 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, KICH, and TGCT as cancer lineages where NLRP14 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NLRP14 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NLRP14 survival associations across molecular data types. NLRP14 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NLRP14 RNA expression–survival associations across cancer types. High NLRP14 expression shows unfavorable associations in THCA, but favorable associations in KIRC, UVM, SKCM, OV and LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NLRP14 RNA expression.
This table summarizes NLRP14 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for NLRP14. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NLRP14 shows lower tumor expression in KICH, THCA, KIRC, LUAD, LUSC and KIRP. The KICH box plot shows higher NLRP14 RNA expression in normal versus tumor tissue (log2 FC = −0.600, t-test p < 0.001).
This table shows molecular features associated with NLRP14 in patient tissues and cancer cell lines. In patient samples, NLRP14 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, NLRP14 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and URINARY_TRACT.
